Investigation of associations between blood pembrolizumab level and clinical factors for immune-related adverse events in Japanese patients with urological cancers

Investigation of associations between blood pembrolizumab level and clinical factors for immune-related adverse events in Japanese patients with urological cancers - Investigation of associations between blood pembrolizumab level and clinical factors for immune-related adverse events in Japanese patients with urological cancers

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000043914

Enrollment

100

Registered

2021-04-13

Start date

2019-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

urological cancers, including renal cell cancer, urothelial cancer, and bladder cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients treated with intravenous pembrolizumab for urological cancer 2. Patients receiving written informed consent

Exclusion criteria

Exclusion criteria: Patients who are judged by physicians as inappropriate for study enrollment

Design outcomes

Primary

Measure	Time frame
Correlations between blood levels of pembrolizumab just before dosing at 2nd administration or later and clinical factors for immune-related adverse events	—

Countries

Japan

Contacts

Public ContactTakafumi Naito

Hamamatsu University School of Medicine Department of Hospital pharmacy

pharmacyham-adm@umin.ac.jp053-435-2763

Outcome results